Analysts at StockNews.com started coverage on shares of Enzo Biochem (NYSE:ENZ – Get Free Report) in a research report issued on Thursday. The brokerage set a “hold” rating on the medical research company’s stock.
Enzo Biochem Price Performance
Shares of Enzo Biochem stock opened at $0.49 on Thursday. Enzo Biochem has a 52 week low of $0.41 and a 52 week high of $1.38. The stock has a 50 day moving average price of $0.63 and a two-hundred day moving average price of $0.93.
Enzo Biochem (NYSE:ENZ – Get Free Report) last announced its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) EPS for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative return on equity of 7.96%.
Institutional Inflows and Outflows
About Enzo Biochem
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
See Also
- Five stocks we like better than Enzo Biochem
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 5 Best Gold ETFs for March to Curb Recession Fears
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.